Author:
Spinelli Marialuigia,Zdanowicz Jarmila A.,Keller Irene,Nicholson Pamela,Raio Luigi,Amylidi-Mohr Sofia,Mosimann Beatrice,Surbek Daniel,Mueller Martin
Abstract
AbstractHypertensive disorders of pregnancy (HDP) contribute substantially to perinatal morbidity and mortality. Epigenetic changes point towards cardio-metabolic dysregulation for these vascular disorders. In early pregnancy, epigenetic changes using cell free DNA (cfDNA) are largely unexplored. We aimed to investigate these in HDP between 11 and 14 weeks of gestation by analysis of cfDNA methylation profiles in patients with hypertensive disorders. We identified patients without chronic hypertension but with subsequent development of preeclampsia (PE) (n = 11), with chronic hypertension (HT) but without PE development (n = 14), and lacking both PE and HT (n = 422). We matched patients according to PE risk factors into three groups (n = 5 each group): (1) PE: no HT but PE development, (2) HT: chronic hypertension but no PE and (3) Control: no PE or HT. We successfully optimized our cfDNA isolation process prior to whole genome bisulfite sequencing. Analysis of cfDNA methylation changes indicate a common predisposition in PE and HT groups, chiefly of maternal origin. Assessment of significant differentially methylated regions and annotated genes point towards a common cardiovascular predisposition in preeclampsia and hypertension groups in the first trimester. We postulate the pivotal role of the maternal cardiovascular system in HDP, which is already evident in the first trimester.
Funder
Department of Obstetrics and Gynecology and Department of Biomedical Research, University of Bern, Bern, Switzerland
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Steegers, E. A., von Dadelszen, P., Duvekot, J. J. & Pijnenborg, R. Pre-eclampsia. Lancet 376, 631–644. https://doi.org/10.1016/s0140-6736(10)60279-6 (2010).
2. Stevens, W. et al. Short-term costs of preeclampsia to the United States health care system. Am. J. Obstet. Gynecol. 217, 237-248.e216. https://doi.org/10.1016/j.ajog.2017.04.032 (2017).
3. Yagel, S., Cohen, S. M. & Goldman-Wohl, D. An integrated model of preeclampsia: A multifaceted syndrome of the maternal cardiovascular-placental-fetal array. Am. J. Obstet. Gynecol. https://doi.org/10.1016/j.ajog.2020.10.023 (2020).
4. Tarca, A. L. et al. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: A longitudinal study. Am. J. Obstet. Gynecol. (2021).
5. Binder, J., Kalafat, E., Palmrich, P., Pateisky, P. & Khalil, A. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension. Am. J. Obstet. Gynecol. https://doi.org/10.1016/j.ajog.2021.03.041 (2021).